-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Raburn Mallory, MD
Senior Vice President,
Clinical Development
Clinical Development
Dr. Mallory is senior vice president, head of clinical development, with leadership responsibility for the clinical development organization and strategic direction of vaccine life-cycle management. He plays a key role in Novavax’ regulatory filings, including the synthesis of clinical data across Novavax’ COVID-19 clinical studies and engagement with global regulatory agencies. Prior to joining the company in 2020, he was Vice President of Clinical Development and the Global Clinical Lead for the COVID-19 and influenza vaccines at AstraZeneca. Earlier, he was a Robert Wood Johnson Clinical Scholar at Johns Hopkins University. Dr. Mallory earned his medical degree from Yale University School Medicine and undergraduate degree from Brown University.